Santhera's idebenone hits top-line in Phase III DMD trial
This article was originally published in Scrip
Santhera Pharmaceticals' Phase III DELIOS study of idebenone in Duchenne muscular dystrophy (DMD) has reached its primary endpoint of delaying the loss of respiratory function compared with placebo, the company says. It is planning to talk to US and EU regulators about the best way forward for the product on the back of the data.
You may also be interested in...
The DMD community faces another setback as FDA pushes back timelines for Santhera and its respiratory drug, pushing the market to question what will come for other DMD treatments in development.
The PureTech Health-founded entity believes it has made a significant step forward in the treatment of schizophrenia with its muscarinic-receptor acting agent KarXT, which could offer a completely new way to address all three symptom domains of the disease.
One of the architects of AstraZeneca’s burgeoning cancer portfolio, oncology R&D head Susan Galbraith is making sure the firm does not rest on its laurels. She talked to In Vivo about what’s coming next from the UK major’s cancer pipeline.